117 related articles for article (PubMed ID: 15334065)
21. A comparative study of p53 gene mutations, protein accumulation, and response to cisplatin-based chemotherapy in advanced ovarian carcinoma.
Righetti SC; Della Torre G; Pilotti S; Ménard S; Ottone F; Colnaghi MI; Pierotti MA; Lavarino C; Cornarotti M; Oriana S; Böhm S; Bresciani GL; Spatti G; Zunino F
Cancer Res; 1996 Feb; 56(4):689-93. PubMed ID: 8630996
[TBL] [Abstract][Full Text] [Related]
22. Relationship between p21 expression and mutation of the p53 tumor suppressor gene in normal and malignant ovarian epithelial cells.
Elbendary AA; Cirisano FD; Evans AC; Davis PL; Iglehart JD; Marks JR; Berchuck A
Clin Cancer Res; 1996 Sep; 2(9):1571-5. PubMed ID: 9816335
[TBL] [Abstract][Full Text] [Related]
23. The role of p53 mutation in BRCA1-associated ovarian cancer.
Rose SL; Buller RE
Minerva Ginecol; 2002 Jun; 54(3):201-9. PubMed ID: 12063435
[TBL] [Abstract][Full Text] [Related]
24. Antitumor effect of intratumoral administration of bone marrow-derived dendritic cells transduced with wild-type p53 gene.
Murakami T; Tokunaga N; Waku T; Gomi S; Kagawa S; Tanaka N; Fujiwara T
Clin Cancer Res; 2004 Jun; 10(11):3871-80. PubMed ID: 15173096
[TBL] [Abstract][Full Text] [Related]
25. Mammary tumor formation in p53- and BRCA1-deficient mice.
Cressman VL; Backlund DC; Hicks EM; Gowen LC; Godfrey V; Koller BH
Cell Growth Differ; 1999 Jan; 10(1):1-10. PubMed ID: 9950212
[TBL] [Abstract][Full Text] [Related]
26. Cooperating oncogenic events in murine mammary tumorigenesis: assessment of ErbB2, mutant p53, and mouse mammary tumor virus.
Zelazny E; Li B; Anagnostopoulos AM; Coleman A; Perkins AS
Exp Mol Pathol; 2001 Jun; 70(3):183-93. PubMed ID: 11417997
[TBL] [Abstract][Full Text] [Related]
27. Chronology and complexities of ovarian tumorigenesis in FORKO mice: age-dependent gene alterations and progressive dysregulation of Major Histocompatibility Complex (MHC) Class I and II profiles.
Aravindakshan J; Chen XL; Sairam MR
Mol Cell Endocrinol; 2010 Nov; 329(1-2):37-46. PubMed ID: 20615452
[TBL] [Abstract][Full Text] [Related]
28. Global deletion of Trp53 reverts ovarian tumor phenotype of the germ cell-deficient white spotting variant (Wv) mice.
Cai KQ; Wang Y; Smith ER; Smedberg JL; Yang DH; Yang WL; Xu XX
Neoplasia; 2015 Jan; 17(1):89-100. PubMed ID: 25622902
[TBL] [Abstract][Full Text] [Related]
29. Mice with alterations in both p53 and Ink4a/Arf display a striking increase in lung tumor multiplicity and progression: differential chemopreventive effect of budesonide in wild-type and mutant A/J mice.
Wang Y; Zhang Z; Kastens E; Lubet RA; You M
Cancer Res; 2003 Aug; 63(15):4389-95. PubMed ID: 12907609
[TBL] [Abstract][Full Text] [Related]
30. Overexpression and mutation of p53 in epithelial ovarian cancer.
Marks JR; Davidoff AM; Kerns BJ; Humphrey PA; Pence JC; Dodge RK; Clarke-Pearson DL; Iglehart JD; Bast RC; Berchuck A
Cancer Res; 1991 Jun; 51(11):2979-84. PubMed ID: 2032235
[TBL] [Abstract][Full Text] [Related]
31. Thrombospondin-1 expression in epithelial ovarian carcinoma: association with p53 status, tumor angiogenesis, and survival in platinum-treated patients.
Alvarez AA; Axelrod JR; Whitaker RS; Isner PD; Bentley RC; Dodge RK; Rodriguez GC
Gynecol Oncol; 2001 Aug; 82(2):273-8. PubMed ID: 11531279
[TBL] [Abstract][Full Text] [Related]
32. The impact of p53 protein core domain structural alteration on ovarian cancer survival.
Rose SL; Robertson AD; Goodheart MJ; Smith BJ; DeYoung BR; Buller RE
Clin Cancer Res; 2003 Sep; 9(11):4139-44. PubMed ID: 14519637
[TBL] [Abstract][Full Text] [Related]
33. Mutation and expression of the TP53 gene in early stage epithelial ovarian carcinoma.
Leitao MM; Soslow RA; Baergen RN; Olvera N; Arroyo C; Boyd J
Gynecol Oncol; 2004 May; 93(2):301-6. PubMed ID: 15099937
[TBL] [Abstract][Full Text] [Related]
34. Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
Reles A; Wen WH; Schmider A; Gee C; Runnebaum IB; Kilian U; Jones LA; El-Naggar A; Minguillon C; Schönborn I; Reich O; Kreienberg R; Lichtenegger W; Press MF
Clin Cancer Res; 2001 Oct; 7(10):2984-97. PubMed ID: 11595686
[TBL] [Abstract][Full Text] [Related]
35. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors.
Kmet LM; Cook LS; Magliocco AM
Cancer; 2003 Jan; 97(2):389-404. PubMed ID: 12518363
[TBL] [Abstract][Full Text] [Related]
36. Loss of expression of the p16 tumor suppressor gene is more frequent in advanced ovarian cancers lacking p53 mutations.
Havrilesky LJ; Alvarez AA; Whitaker RS; Marks JR; Berchuck A
Gynecol Oncol; 2001 Dec; 83(3):491-500. PubMed ID: 11733961
[TBL] [Abstract][Full Text] [Related]
37. p53 expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry.
Henriksen R; Strang P; Wilander E; Bäckström T; Tribukait B; Oberg K
Gynecol Oncol; 1994 Jun; 53(3):301-6. PubMed ID: 8206402
[TBL] [Abstract][Full Text] [Related]
38. Female mice chimeric for expression of the simian virus 40 TAg under control of the MISIIR promoter develop epithelial ovarian cancer.
Connolly DC; Bao R; Nikitin AY; Stephens KC; Poole TW; Hua X; Harris SS; Vanderhyden BC; Hamilton TC
Cancer Res; 2003 Mar; 63(6):1389-97. PubMed ID: 12649204
[TBL] [Abstract][Full Text] [Related]
39. Molecular alterations and lung tumors in p53 mutant mice exposed to cigarette smoke.
De Flora S; Balansky RM; D'Agostini F; Izzotti A; Camoirano A; Bennicelli C; Zhang Z; Wang Y; Lubet RA; You M
Cancer Res; 2003 Feb; 63(4):793-800. PubMed ID: 12591728
[TBL] [Abstract][Full Text] [Related]
40. p53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovary.
Leonhardt K; Einenkel J; Sohr S; Engeland K; Horn LC
Int J Gynecol Pathol; 2011 Sep; 30(5):417-24. PubMed ID: 21804388
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]